首页> 外国专利> METHOD FOR PREOPERATIVE PREDICTION OF THE RISK OF RECURRENCE IN PATIENTS WITH STAGE T1 ENDOMETRIAL CANCER

METHOD FOR PREOPERATIVE PREDICTION OF THE RISK OF RECURRENCE IN PATIENTS WITH STAGE T1 ENDOMETRIAL CANCER

机译:术前预测阶段T1子宫内膜癌患者复发风险的方法

摘要

FIELD: oncology and molecular biology.;SUBSTANCE: invention relates to oncology and molecular biology. In the preoperative period, venous blood is examined by multicolor flow cytometry using monoclonal antibodies to EpCam, CD45, CD44, CD24, N-Cadherin labeled with various fluorochromes, and NucBlue Live cell stain ready probes reagent nuclear dye. Then determine the number of Epcam + CD45- (cells/ml of blood) (X1), the number of CTCs with the Epcam + CD45-CD44-CD24-Ncadherin + phenotype (cells/ml) (X2), the number of stem CTCs without Epcam expression on the membrane with the Epcam phenotype (m) -CD45-CD44 + CD24- (cells/ml) (X3); the number of atypical/hybrid forms of CTCs with the Epcam + CD45 + phenotype (cells/ml) (X4). Then the value of the regression equation Υ is calculated according to the original formula. At Υ≥0.5, a high is determined, and at Υ<0.5, a low risk of endometrial cancer recurrence is determined.;EFFECT: method allows to reduce invasiveness and increase the accuracy, sensitivity and specificity of the method by 87.5% and 96.7%, respectively.;1 cl, 2 tbl, 2 ex
机译:领域:肿瘤学和分子生物学。;物质:发明涉及肿瘤学和分子生物学。在术前期间,使用单克隆抗体对EPCAM,CD45,CD44,CD24,N-Cadherin标记的多色流式细胞仪检查静脉血液,标记为各种荧光染料,Nucblue活细胞染色准备就绪探针试剂核染料。然后确定EPCAM + CD45-(细胞/ mL血液)(X1)的数量,用EPCAM + CD45-CD44-CD24-Ncadherin +表型(细胞/ mL)(X2),茎的数量没有EPCAM表达的CTC与EPCAM表型(M)-CD45-CD44 + CD24-(细胞/ mL)(X3);具有EPCAM + CD45 +表型(细胞/ mL)的CTC的非典型/杂交形式的数量(X4)。然后根据原始公式计算回归方程υ的值。在≥0.5,确定高,并且在≥<0.5时,确定子宫内膜癌症复发的低风险。;效果:方法允许通过87.5%和96.7来降低侵袭性并提高方法的准确性,灵敏度和特异性。分别为%。; 1 cl,2 tbl,2前

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号